Neo Ivy Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Neo Ivy Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-43,355	Closed	-$2.45M	–	370
2026 Q1	$2.45M	Buy	+43,355	New	+$2.53M	0.65%	55
2025 Q3	–	Sell	-5,254	Closed	-$289K	–	398
2025 Q2	$289K	Sell	5,254 -19,834	-79%	-$1.17M	0.09%	252
2025 Q1	$1.77M	Buy	+25,088	New	+$1.69M	0.56%	77
2024 Q4	–	Sell	-21,020	Closed	-$1.48M	–	280
2024 Q3	$1.48M	Buy	21,020 +20,116	+2,225%	+$1.68M	0.48%	85
2024 Q2	$74K	Buy	+904	New	+$75.3K	0.01%	211
2022 Q4	–	Sell	-798	Closed	-$68K	–	345
2022 Q3	$68K	Buy	798 +55	+7%	+$4.9K	0.18%	189
2022 Q2	$61K	Buy	+743	New	+$59.2K	0.16%	208
2021 Q4	–	Sell	-1,044	Closed	-$129K	–	448
2021 Q3	$129K	Buy	+1,044	New	+$82.4K	0.15%	212
2021 Q2	–	Sell	-505	Closed	-$38K	–	456
2021 Q1	$38K	Sell	505 -182	-26%	-$14.9K	0.04%	355
2020 Q4	$60K	Buy	+687	New	+$54.5K	0.07%	293
2020 Q3	–	Sell	-1,044	Closed	-$129K	–	471
2020 Q2	$129K	Buy	1,044 +688	+193%	+$68.4K	0.15%	212
2020 Q1	$30K	Buy	+356	New	+$30.7K	0.05%	352
2019 Q3	–	Sell	-3,527	Closed	-$302K	–	292
2019 Q2	$302K	Buy	+3,527	New	+$302K	0.17%	187

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Neo Ivy Capital Management's BMRN Position: Q2 2026 in Review

Neo Ivy Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 43,355 shares — an estimated $2.45M sold.

Neo Ivy Capital Management first reported a position in BMRN in Q2 2019 and held it in 13 quarters. The position peaked at $2.45M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Neo Ivy Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Neo Ivy Capital Management sold 43,355 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.45M.
Neo Ivy Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2019 and held it in 13 quarters.
Neo Ivy Capital Management's BioMarin Pharmaceuticals position peaked at $2.45M in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.